Ligand Pharmaceuticals Incorporated (LGND) is a renowned biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients in need of effective treatment solutions. The company was founded in 1987 and is headquartered in San Diego, California. Known for its pioneering work, Ligand Pharmaceuticals stands out in the biopharmaceutical industry for its unique approach to developing a variety of drugs that address critical unmet medical needs.
Ligand Pharmaceuticals explores multiple avenues of research, covering many areas of disease and therapies. The company's drug discovery and development efforts pertains to a wide range of therapeutic sectors, including oncology, metabolic disorders, respiratory disorders, and more. Ligand Pharmaceuticals has constructed one of the industry's most diverse portfolios, with more than 180 programs under development by partners.
At the heart of Ligand is its patented platform technology known as OmniAb®. This platform allows Ligand to generate a broad range of fully human therapeutic antibodies with superior potency and selectivity. Beyond OmniAb®, Ligand operates with a number of other innovative technologies such as LTP Technology™, Captisol® and more. The company's Captisol® technology, for instance, is a proprietary cyclodextrin formulation that improves solubility, stability, and bioavailability of active pharmaceutical ingredients (APIs).
The business model of Ligand Pharmaceuticals is unique and visionary; instead of focusing on the risky and costly process of drug discovery by itself, the company forms licenses and collaborations with other pharmaceutical companies. They utilize Ligand's advanced technology platforms and benefit from the company's expertise to develop and commercialize their own drugs. This approach not only enhances Ligand's revenue streams through licensing fees, milestone payments, and royalties on sales, but also accelerates the availability of groundbreaking drugs to patients around the world who desperately need them.
Despite its extensive collaborations, Ligand Pharmaceuticals still maintains a selective group of drugs in its own developmental pipeline, enabling it to directly contribute to the pharmaceutical landscape. The company follows strict governance and quality-control measures to ensure the provision of high-quality, safe, and effective medicines.
In the changing landscape of the biopharmaceutical industry, Ligand Pharmaceuticals continues to be a bold and innovative leader, revolutionizing drug discovery and development, and consistently placing patient needs at the heart of their activities.